The Keynote-826 study, that combined pembrolizumab with chemotherapy and bevacizumab, has led to FDA-approval of pembrolizumab as first-line treatment for advanced cervical cancer patients (with a PD-L1 CPS of one or higher) [94]. The gene discussed is CD274; the disease is cervical cancer.